Please log in to view this page
Username
Password
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
